Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433595 | 0.92 | GRIN2B (0.52) | CA1CA2GRIN2BIDO1SIGMAR1 | |
| SCHEMBL1019088 | 0.82 | KDM1A (0.57) | GRIN2BMAOAMAOB | |
| SCHEMBL20061143 | 0.81 | CA1 (0.42) | CA1CA2GRIN2BIDO1SIGMAR1 | |
| SCHEMBL20061120 | 0.81 | CA1 (0.42) | CA1CA2GRIN2BIDO1SIGMAR1 | |
| SCHEMBL459537 | 0.79 | GRIN2B (0.65) | CA1CA2GRIN2BSIGMAR1MTNR1A | |
| SCHEMBL714537 | 0.78 | SIGMAR1 (0.53) | CA1CA2GRIN2BIDO1SIGMAR1 | |
| SCHEMBL6904134 | 0.78 | CA1 (0.54) | CA1CA2GRIN2BIDO1SIGMAR1 | |
| SCHEMBL3531863 | 0.78 | GRIN2B (0.50) | CA1CA2GRIN2BIDO1SIGMAR1 | |
| SCHEMBL1488586 | 0.78 | CA1 (0.48) | CA1CA2GRIN2BIDO1SIGMAR1 | |
| SCHEMBL1691712 | 0.78 | CA1 (0.54) | CA1CA2GRIN2BIDO1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373191-B1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-06-05 | — | — | EP | claimed |
| US-10035824-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180079782-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2018-03-22 | — | — | US | disclosed |
| EP-0861837-B1 | 2-Aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2004-04-28 | — | — | EP | disclosed |
| EP-0861837-A1 | 2-Aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079782-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | CA1 2973/4885CA2 3337/4885GRIN2B 3606/4885 |
| US-10035824-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | IL23R, IL1RN, VIP | CA1 2811/4885CA2 3614/4885GRIN2B 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.